A significantly greater proportion of amyotrophic lateral sclerosis (ALS) patients with less severe disease showed slower ALS progression with the investigational cell-based therapy NurOwn relative to a placebo. These are the findings of another post-hoc analysis of data from NurOwn’s Phase 3 clinical trial (NCT03280056), further supporting the…
We decorated for Christmas this past weekend. The kids and I went out into the woods, and my 12-year-old son, Isaac, cut down a balsam fir. My 15-year-old daughter, Sara, carried it back to our house, and we put it in the tree stand in the living room. When we…
Calling it the “biggest challenge” of his life, a U.K. rugby fan and motor neurone disease (MND) advocate, Martyn Clarke, is undertaking a Herculean effort — seven Half Ironman triathlons in seven days — to raise funds for the MND Association. Clarke, 47, was inspired to push himself to…
“And I hope when I get old I don’t sit around thinking about it But I probably will Yeah, just sitting back trying to recapture A little of the glory Well time slips away and leaves you with nothing, mister, but Boring stories of Glory days …” Bruce Springsteen’s…
Thanks to the implementation of proactive safety measures for the COVID-19 pandemic, Mitsubishi Tanabe Pharma America (MTPA) has enrolled at least 33 adults with amyotrophic lateral sclerosis (ALS) in its ongoing REFINE-ALS biomarker study. “ALS patient needs remain MTPA’s primary focus, so it was a priority to address the…
When I was diagnosed with ALS, one of the many things that changed was my relationship with clothes. I used to buy and wear clothes that caught my fancy. Now, living with ALS means I’m choosing comfort and the ease of getting myself dressed over the latest trend. Has this…
Most of the initial amyotrophic lateral sclerosis (ALS) patients enrolled in Cytokinetics’ COURAGE-ALS Phase 3 trial testing its experimental therapy reldesemtiv have moderate-to-fast progressing disease at study entry. An analysis shows that, as intended, COURAGE-ALS is increasing the proportion of patients with rapidly progressing disease compared with the…
An oral suspension formulation of edaravone (MT-1186) is safe and well-tolerated in adults with amyotrophic lateral sclerosis (ALS), according to interim, six-month data from a Phase 3 clinical trial. In addition, exploratory efficacy results suggest that edaravone’s experimental oral formulation may slow patients’ functional decline to a similar level…
Before his recent death, motor neuron disease (MND) patient Anthony Walsh had the opportunity to try a prototype Toyota Human Support Robot (HSR), providing a glimpse into the kind of technology that could be used to help people with amyotrophic lateral sclerosis and other MNDs with everyday tasks. Walsh, who was…
My husband Todd’s lung strength is weak from ALS. He’s gotten sick a few times in the last several years, and each time we wondered if he would pull through. It was scary, and it has caused us to calculate the risk of going out in public or receiving…
Get regular updates to your inbox.
